By Fineline Cube 
Nanjing Pharmaceutical Group Co., Ltd. (SHA: 600713) has unveiled a strategic plan to establish a dedicated corporate investment fund with a total commitment of up to RMB 450 million (USD 62 million). The fund’s primary objective is to acquire controlling equity stakes in two Chinese medical technology firms, Beijing Datsing Biotechnology Co., Ltd. and Beijing Kejian Technology Co., Ltd., as part of Nanjing Pharma’s vertical integration strategy.
Transaction Structure & Key Parties
| Item | Detail |
|---|---|
| Lead Investor | Nanjing Pharmaceutical Group (59.90% stake in fund) |
| Fund Partners | Nanjing Xingong Emerging Industry Investment Management; Nanjing Xingong Medical Healthcare Chain Strengthening M&A Fund |
| Fund Size | Up to RMB 450M (USD 62M) from Nanjing Pharma; Total equity cap RMB 750M (USD 110M) |
| Target 1 | Beijing Datsing Biotechnology Co., Ltd. (44.95% stake) |
| Target 2 | Beijing Kejian Technology Co., Ltd. (50.98% stake) |
| Total Valuation Cap | RMB 1.5 billion (USD 219 million) for both targets combined |
| Accounting Treatment | Full consolidation of the fund and both target companies into Nanjing Pharma’s financials post-closing |
Strategic Rationale
- Vertical Integration: The acquisitions are designed to strengthen Nanjing Pharma’s position across the healthcare value chain by integrating upstream medical technology capabilities.
- Controlled Investment: By structuring the deal through a majority-owned fund, Nanjing Pharma gains operational control while managing its direct capital outlay and balance sheet impact.
- Portfolio Synergy: Datsing Bio and Kejian Tech are expected to complement Nanjing Pharma’s existing product portfolio and distribution network, creating cross-selling opportunities and operational efficiencies.
- Financial Engineering: The use of a special-purpose vehicle (SPV) allows for a clean consolidation path, immediately bringing the targets’ revenues and assets onto Nanjing Pharma’s books.
Market Context & Implications
- Chinese Pharma Consolidation: This move reflects a broader trend of established Chinese pharmaceutical companies using M&A to diversify beyond traditional drug manufacturing into higher-growth medtech segments.
- Capital Deployment: With a clear cap on total valuation and investment, Nanjing Pharma demonstrates disciplined capital allocation, mitigating overpayment risk in a competitive acquisition market.
- Regulatory Path: As a domestic transaction involving a Shanghai-listed company, the deal is subject to standard Chinese regulatory and shareholder approval processes, with final terms contingent on definitive agreements.
- Investor Impact: Successful integration could enhance Nanjing Pharma’s margins and growth profile, offering investors exposure to the rapidly expanding Chinese medical technology sector through an established pharmaceutical platform.
Forward-Looking Statements
This brief is based on a public announcement from Nanjing Pharmaceutical Group. The proposed transactions are subject to the execution of definitive agreements, regulatory approvals, and other customary closing conditions. The final acquisition ratios, pricing, and timing may differ from the current proposal. There can be no assurance that the transactions will be completed as described.-Fineline Info & Tech